HANGZHOU TIGERMED CONSULTING CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.7 CNY | +8.85% |
|
+16.24% | +4.97% |
| 04-25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
| 04-25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
Chart calendar Hangzhou Tigermed Consulting Co., Ltd
601a0f7c3040f3.rRUFKldwIE6MNK5T22AhTVirgKyTnjMD6H5loa9nZjE.3CRJXQEieX66d9kVmBB2HW3f-N_l2WRphzEwwuxKKmvfYXxSET9HANVEng~05071ea947a7bc91a7a24c61adae044b
Upcoming events on Hangzhou Tigermed Consulting Co., Ltd
Past events on Hangzhou Tigermed Consulting Co., Ltd
| 24/04/2024 | Q1 2024 Earnings Release |
| 28/03/2024 11:10 | Q4 2023 Earnings Release |
| 21/03/2024 07:00 | Extraordinary Shareholders Meeting |
| 27/10/2023 | Q3 2023 Earnings Release |
| 25/08/2023 11:39 | Q2 2023 Earnings Release |
| 23/05/2023 03:00 | Annual General Meeting |
| 24/04/2023 | Q1 2023 Earnings Release |
| 28/03/2023 | Q4 2022 Earnings Release |
| 23/11/2022 07:00 | Extraordinary Shareholders Meeting |
| 24/10/2022 | Q3 2022 Earnings Release |
| 25/08/2022 12:05 | Interim 2022 Earnings Release |
| 20/05/2022 03:00 | Annual General Meeting |
| 25/04/2022 | Q1 2022 Earnings Release |
| 28/03/2022 12:22 | FY 2021 Earnings Release |
| 21/10/2021 | Q3 2021 Earnings Release |
| 15/10/2021 08:00 | Extraordinary Shareholders Meeting |
| 26/09/2021 | Extraordinary Shareholders Meeting |
| 24/08/2021 | Interim 2021 Earnings Call |
| 24/08/2021 | Interim 2021 Earnings Release |
| 09/08/2021 03:00 | Extraordinary Shareholders Meeting |
Past dividends on Hangzhou Tigermed Consulting Co., Ltd
| 06/07/2023 | Annual 0.55 CNY |
| 30/05/2022 | Annual 0.5 CNY |
| 31/05/2021 | Annual 0.3 CNY |
| 21/05/2020 | Annual 0.278 CNY |
| 30/06/2019 | Annual 0.35 CNY |
| 29/05/2018 | Final Payment 0.2 CNY |
| 18/09/2017 | Interim Payment 0.1 CNY |
| 19/05/2016 | Annual 0.1 CNY |
| 19/05/2015 | Annual 0.2 CNY |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million CNY | Released Forecast Spread | 2 803 2 966 -5.49% | 3 192 3 231 -1.19% | 5 214 4 526 15.2% | 7 085 7 133 -0.67% | 7 384 7 820 -5.57% | 8 097 |
|
EBITDA Million CNY | Released Forecast Spread | 1 132 927 22.15% | 2 308 1 037 122.57% | 3 820 1 348 183.36% | 2 963 3 324 -10.86% | 2 949 2 854 3.33% | 2 052 |
|
EBIT Million CNY | Released Forecast Spread | 1 085 886 22.46% | 2 222 913 143.36% | 3 697 3 009 22.85% | 2 678 2 014 32.95% | 2 610 3 065 -14.85% | 2 798 |
|
Earnings before Tax (EBT) Million CNY | Released Forecast Spread | 1 089 965 12.84% | 2 219 1 989 11.57% | 3 690 2 857 29.12% | 2 595 3 039 -14.62% | 2 490 2 992 -16.77% | 2 239 |
|
Net income Million CNY | Released Forecast Spread | 842 733 14.88% | 1 750 1 631 7.29% | 2 879 2 259 27.44% | 2 016 2 394 -15.78% | 2 027 2 358 -14.07% | 1 759 |
|
EPS CNY | Released Forecast Spread | 1,13 0,98 15.54% | 2,19 1,92 14.32% | 3,30 2,59 27.48% | 2,33 2,79 -16.58% | 2,34 2,70 -13.23% | 2,01 |
| Announcement Date | 28/02/20 | 29/03/21 | 10/03/22 | 28/03/23 | 28/03/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million CNY | Released Forecast Spread | 1 818 699 160.18% | 1 776 1 376 29.09% | 3 594 2 982 20.53% | 1 812 1 755 3.26% | 1 679 1 549 8.42% | 1 805 1 859 -2.95% | 1 906 2 261 -15.68% | 3 711 3 879 -4.33% | 1 940 1 965 -1.29% | 1 734 2 012 -13.82% | 1 660 2 216 -25.08% | 2 124 | 2 254 | 2 165 | ||
|
EBIT Million CNY | Released Forecast Spread | 654 189 245.77% | 827 338 144.36% | 906 746 21.5% | 520 509 2.18% | 581 667 -12.77% | 418 462 -9.46% | 481 567 -15.25% | 1 599 950 68.27% | 713 700 1.83% | 404 | ||||||
|
Earnings before Tax (EBT) Million CNY | Released Forecast Spread | 656 843 -22.15% | 824 705 16.89% | 1 480 1 223 21% | 526 933 -43.6% | 589 1 026 -42.58% | 631 676 -6.66% | 968 787 23% | 1 599 1 310 22.07% | 715 839 -14.78% | 176 464 -62.11% | 526 | 711 | 683 | |||
|
Net income Million CNY | Released Forecast Spread | 518 687 -24.54% | 674 580 16.23% | 1 192 990 20.4% | 413 758 -45.59% | 411 862 -52.28% | 568 551 3.12% | 820 616 33.04% | 1 388 1 090 27.37% | 491 735 -33.19% | 147 451 -67.44% | 409 | 554 | 533 | |||
|
EPS CNY | Released Forecast Spread | 0,60 0,63 -4.13% | 0,78 0,64 21.4% | 0,48 0,66 -27.61% | 0,47 0,62 -24.12% | 0,66 0,61 7.5% | 0,95 0,51 88.12% | 0,56 0,71 -21.6% | 0,17 0,46 -62.97% | 0,27 0,53 -49.06% | 0,49 | 0,58 | 0,65 | 0,66 | 0,68 | ||
| Announcement Date | 26/04/22 | 25/08/22 | 25/08/22 | 25/10/22 | 28/03/23 | 25/04/23 | 25/08/23 | 25/08/23 | 27/10/23 | 28/03/24 | 25/04/24 | - | - | - | - | - |
More events
Past sector events for Hangzhou Tigermed Consulting Co., Ltd
| 26/04/2024 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 06:00 | BB BIOTECH AG: Q1 2024 Earnings Release |
| 25/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 25/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 25/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 12:00 | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 07:00 | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- 300347 Stock
- Calendar Hangzhou Tigermed Consulting Co., Ltd
